Adequate bone marrow reserve as evidenced by:
Bone marrow reserve which, in the clinical judgment of the Principal Investigator, is not adequate for participation in this trial.
Patients must have adequate bone marrow reserve as evidenced by:
Poor bone marrow reserve.
Adequate bone marrow reserve
Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
Adequate organ function within 14 days of study registration including:\r\n* Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) >= 1.0 x 10^9/L
Adequate bone marrow reserve as demonstrated by :
Subjects with recent history of inadequate bone marrow reserve as demonstrated by previous transfusions except for acute blood loss (e.g. surgery) in the month prior to screening
Recent history of inadequate bone marrow reserve as demonstrated by the following:
Adequate organ function and bone marrow reserve as indicated by the following laboratory assessments performed at screening.
Inadequate organ function or bone marrow reserve as demonstrated by the following laboratory values:
Inadequate bone marrow reserve or organ function.
Patients must have adequate bone marrow reserve as evidenced by:
Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at baseline
Poor bone marrow reserve.
Adequate bone marrow reserve (neutrophils > 1000/mm3 and platelets > 80000/ mm3)
Adequate bone marrow reserve without transfusions defined as:
Poor bone marrow reserve.
Have adequate organ reserve as determined by laboratory test results obtained within 2 weeks prior to Study Day 1 as indicated below:
Inadequate bone marrow reserve or organ function
Inadequate marrow reserve assessed by hematologic laboratory parameters
Inadequate bone marrow reserve or organ function
Inadequate bone marrow reserve
Inadequate bone marrow reserve or organ function
Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
Adequate bone marrow reserve as evidenced by ANC > 1.0x10^9/L;Platelet > 50x10^9/L
Adequate bone marrow reserve
Two weeks must have elapsed since completion of prior chemotherapy, minor surgery, radiotherapy (provided that no more than 25% of bone marrow reserve has been irradiated)
Two weeks must have elapsed since completion of prior chemotherapy, minor surgery, radiotherapy (provided that no more than 25% of bone marrow reserve has been irradiated)
Adequate bone marrow reserve, hepatic and renal function, as demonstrated by:
Patients who have had radiation to the pelvis or other bone marrow-bearing sites will be considered on a case by case basis and may be excluded if the bone marrow reserve is not considered adequate (> 25% of bone marrow)
Has adequate bone marrow reserve, hepatic and renal function, as demonstrated by:
Has adequate bone marrow reserve as evidenced by:
Subject must have adequate hematologic reserve
Inadequate bone marrow reserve
Patient with glioblastoma must have adequate bone marrow and immune reserve, as documented by:
Have adequate bone marrow reserve and organ function at screening as follows:
Adequate bone marrow reserve as demonstrated by
The patient has adequate bone marrow reserve: • Absolute neutrophil count (ANC) > 0.5 × 10^9/L
Patients must have adequate physiologic reserve as evidenced by:
Patient has adequate bone marrow reserve, as evidenced by:
Patients who have had radiation to the pelvis or other bone marrow-bearing sites will be considered on a case by case basis and may be excluded if the bone marrow reserve is not considered adequate (> 25% of bone marrow irradiated)
Adequate bone marrow reserve as defined per protocol;
Have adequate bone marrow reserve defined as:
Patients who have undergone prior stem cell transplant will not be excluded from study entry as long as adequate marrow reserve is demonstrated (refer to hematologic parameters)
Subjects with recent history of inadequate bone marrow reserve as demonstrated by previous transfusions except for acute blood loss (e.g. surgery) in the month prior to screening
Adequate bone marrow reserve
Adequate hepatic reserve
Adequate bone marrow reserve and renal and hepatic function within 28 days before the first dose of study drug on the basis of the defined laboratory parameters.
